Drug intelligence / Profile preview

L608

Development stage: Phase 1
Lead developer: Pharmosa Biopharm
Modality: Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Inhalation

Overview

L608 is a liposomal formulation of iloprost developed for inhalation use in the treatment of pulmonary arterial hypertension (PAH). The formulation encapsulates prostacyclin drugs in liposomes, providing localized and sustained release characteristics. It is designed to reduce dosing frequency and mitigate burst release-related local irritation and systemic side effects such as hypotension due to plasma peaks.

Other names: L608 inhalation SolutionL-608 inhalation SolutionL 608 inhalation Solution

Targets

PTGIR (Prostanoid IP Receptor)

Beyond the preview

Go deeper on L608.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on L608.

Explore the full profile